StockData
GeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS) stock

WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$51.02−1.35 (-2.58%)

Close on Nov 16, 2026Market cap $1.52BP/E –Yield –

GeneDx cash

Cash and short-term investments held at the end of each period.

GeneDx's cash was $132.55M at Jun 30, 2026. For fiscal 2025 it was $171.28M, up 20.5% from the year before. The highest annual figure on record is $401.47M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$171.28M+20.5%
FY2024Dec 31, 2024$142.18M+8.4%
FY2023Dec 31, 2023$131.14M+5.8%
FY2022Dec 31, 2022$123.90M-69.1%
FY2021Dec 31, 2021$401.47M+271.3%
FY2020Dec 31, 2020$108.13M-6.0%
FY2019Dec 31, 2019$115.01M+9662.8%
FY2018Dec 31, 2018$1.18M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$132.55M-2.2%
Q1 FY2026Mar 31, 2026$170.69M+6.6%
Q4 FY2025Dec 31, 2025$171.28M+20.5%
Q3 FY2025Sep 30, 2025$155.08M+32.0%
Q2 FY2025Jun 30, 2025$135.55M+25.7%
Q1 FY2025Mar 31, 2025$160.15M+40.6%
Q4 FY2024Dec 31, 2024$142.18M+8.4%
Q3 FY2024Sep 30, 2024$117.45M+2.8%
Q2 FY2024Jun 30, 2024$107.85M-31.5%
Q1 FY2024Mar 31, 2024$113.90M-47.0%
Q4 FY2023Dec 31, 2023$131.14M+5.8%
Q3 FY2023Sep 30, 2023$114.30M-44.4%
Q2 FY2023Jun 30, 2023$157.56M-47.3%
Q1 FY2023Mar 31, 2023$214.94M-32.0%
Q4 FY2022Dec 31, 2022$123.90M-69.1%
Q3 FY2022Sep 30, 2022$205.73M-55.5%
Q2 FY2022Jun 30, 2022$299.02M+701.0%
Q1 FY2022Mar 31, 2022$315.90M+354.7%
Q4 FY2021Dec 31, 2021$401.47M+271.3%
Q3 FY2021Sep 30, 2021$462.18M+230.9%
Q2 FY2021Jun 30, 2021$37.33M-67.5%
Q1 FY2021Mar 31, 2021$69.48M+5798.1%
Q4 FY2020Dec 31, 2020$108.13M–
Q3 FY2020Sep 30, 2020$139.68M–
Q4 FY2019Dec 31, 2019$115.01M–
Q4 FY2018Dec 31, 2018$1.18M–

More GeneDx figures

See a number that looks wrong?